Chiesi Farmaceutici SpA – Product Pipeline Review

Global Markets Direct’s, ‘Chiesi Farmaceutici SpA – Product Pipeline Review – 2016’, provides an overview of the Chiesi Farmaceutici SpA’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Chiesi Farmaceutici SpA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Chiesi Farmaceutici SpA

The report provides overview of Chiesi Farmaceutici SpA including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Chiesi Farmaceutici SpA’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Chiesi Farmaceutici SpA’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Chiesi Farmaceutici SpA’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chiesi Farmaceutici SpA

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chiesi Farmaceutici SpA’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Chiesi Farmaceutici SpA Snapshot 6

Chiesi Farmaceutici SpA Overview 6

Key Facts 6

Chiesi Farmaceutici SpA - Research and Development Overview 7

Key Therapeutic Areas 7

Chiesi Farmaceutici SpA - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

Pipeline Products - Out-Licensed Products 15

Out-Licensed Products/Combination Treatment Modalities 16

Chiesi Farmaceutici SpA - Pipeline Products Glance 17

Chiesi Farmaceutici SpA - Late Stage Pipeline Products 17

Phase III Products/Combination Treatment Modalities 17

Chiesi Farmaceutici SpA - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

Chiesi Farmaceutici SpA - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Chiesi Farmaceutici SpA - Unknown Stage Pipeline Products 21

Unknown Products/Combination Treatment Modalities 21

Chiesi Farmaceutici SpA - Drug Profiles 22

(beclomethasone dipropionate + formoterol fumarate + glycopyrrolate) - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

budesonide - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

CHF-5633 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

CHF-6001 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

CHF-6297 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

CPD-15 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Drugs for Bronchopulmonary Dysplasia - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

glycopyrrolate - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

melatonin - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

meropenem - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Recombinant Enzymes for Rare Diseases - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Recombinant Protein for Neonatal Respiratory Distress Syndrome - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

Recombinant Protein to Target NGF for Undisclosed Indication - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Small Molecule to Inhibit Neutrophil Elastase for Respiratory Diseases - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

Small Molecule to Target Beta 2 Adrenergic Receptor and Muscarinic Acetylcholine Receptor M3 for Asthma and COPD - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Small Molecules for Neonatal Abstinence Syndrome - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

TRP-601 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

velmanase alfa - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Chiesi Farmaceutici SpA - Pipeline Analysis 45

Chiesi Farmaceutici SpA - Pipeline Products by Target 45

Chiesi Farmaceutici SpA - Pipeline Products by Route of Administration 47

Chiesi Farmaceutici SpA - Pipeline Products by Molecule Type 48

Chiesi Farmaceutici SpA - Pipeline Products by Mechanism of Action 49

Chiesi Farmaceutici SpA - Dormant Projects 51

Chiesi Farmaceutici SpA - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 53

beclomethasone dipropionate SR 53

carmoterol 53

indantadol 53

Porphozym 53

Chiesi Farmaceutici SpA - Company Statement 54

Chiesi Farmaceutici SpA - Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 57

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Chiesi Farmaceutici SpA, Key Facts 6

Chiesi Farmaceutici SpA – Pipeline by Indication, 2016 9

Chiesi Farmaceutici SpA – Pipeline by Stage of Development, 2016 10

Chiesi Farmaceutici SpA – Monotherapy Products in Pipeline, 2016 11

Chiesi Farmaceutici SpA – Combination Treatment Modalities in Pipeline, 2016 12

Chiesi Farmaceutici SpA – Partnered Products in Pipeline, 2016 13

Chiesi Farmaceutici SpA – Partnered Products/ Combination Treatment Modalities, 2016 14

Chiesi Farmaceutici SpA – Out-Licensed Products in Pipeline, 2016 15

Chiesi Farmaceutici SpA – Out-Licensed Products/ Combination Treatment Modalities, 2016 16

Chiesi Farmaceutici SpA – Phase III, 2016 17

Chiesi Farmaceutici SpA – Phase II, 2016 18

Chiesi Farmaceutici SpA – Phase I, 2016 19

Chiesi Farmaceutici SpA – Preclinical, 2016 20

Chiesi Farmaceutici SpA – Unknown, 2016 21

Chiesi Farmaceutici SpA – Pipeline by Target, 2016 46

Chiesi Farmaceutici SpA – Pipeline by Route of Administration, 2016 47

Chiesi Farmaceutici SpA – Pipeline by Molecule Type, 2016 48

Chiesi Farmaceutici SpA – Pipeline Products by Mechanism of Action, 2016 50

Chiesi Farmaceutici SpA – Dormant Developmental Projects,2016 51

Chiesi Farmaceutici SpA – Discontinued Pipeline Products, 2016 52

Chiesi Farmaceutici SpA, Subsidiaries 57

List of Figures

List of Figures

Chiesi Farmaceutici SpA – Pipeline by Top 10 Indication, 2016 8

Chiesi Farmaceutici SpA – Pipeline by Stage of Development, 2016 10

Chiesi Farmaceutici SpA – Monotherapy Products in Pipeline, 2016 11

Chiesi Farmaceutici SpA – Combination Treatment Modalities in Pipeline, 2016 12

Chiesi Farmaceutici SpA – Out-Licensed Products in Pipeline, 2016 15

Chiesi Farmaceutici SpA – Pipeline by Top 10 Target, 2016 45

Chiesi Farmaceutici SpA – Pipeline by Route of Administration, 2016 47

Chiesi Farmaceutici SpA – Pipeline by Molecule Type, 2016 48

Chiesi Farmaceutici SpA – Pipeline Products by Top 10 Mechanism of Action, 2016 49

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared